Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(3-4):535–537. doi: 10.1038/sj.bjc.6690084

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

M Raderer 1, G Hamilton 2, A Kurtaran 3, J Valencak 1, I Haberl 4, O Hoffmann 5, G V Kornek 1, F Vorbeck 6, M H L Hejna 1, I Virgolini 3, W Scheithauer 1
PMCID: PMC2362412  PMID: 10027326

Abstract

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8–7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues. © 1999 Cancer Research Campaign

Keywords: lanreotide, pancreatic cancer, somatostatin receptors

Full Text

The Full Text of this article is available as a PDF (56.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthony L., Johnson D., Hande K., Shaff M., Winn S., Krozely M., Oates J. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217–223. doi: 10.3109/02841869309083915. [DOI] [PubMed] [Google Scholar]
  2. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P., Petcher T. J., Pless SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982 Sep 13;31(11):1133–1140. doi: 10.1016/0024-3205(82)90087-x. [DOI] [PubMed] [Google Scholar]
  3. Buscail L., Saint-Laurent N., Chastre E., Vaillant J. C., Gespach C., Capella G., Kalthoff H., Lluis F., Vaysse N., Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 1996 Apr 15;56(8):1823–1827. [PubMed] [Google Scholar]
  4. Canobbio L., Boccardo F., Cannata D., Gallotti P., Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer. 1992 Feb 1;69(3):648–650. doi: 10.1002/1097-0142(19920201)69:3<648::aid-cncr2820690308>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  5. Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol. 1995 Mar;132(3):320–325. doi: 10.1530/eje.0.1320320. [DOI] [PubMed] [Google Scholar]
  6. Glimelius B., Hoffman K., Sjödén P. O., Jacobsson G., Sellström H., Enander L. K., Linné T., Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996 Aug;7(6):593–600. doi: 10.1093/oxfordjournals.annonc.a010676. [DOI] [PubMed] [Google Scholar]
  7. Huguier M., Samama G., Testart J., Mauban S., Fingerhut A., Nassar J., Houry S., Jaeck D., De Mestier P., Favre J. P. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. Am J Surg. 1992 Oct;164(4):348–353. doi: 10.1016/s0002-9610(05)80903-1. [DOI] [PubMed] [Google Scholar]
  8. Janson E. T., Gobl A., Kälkner K. M., Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res. 1996 Jun 1;56(11):2561–2565. [PubMed] [Google Scholar]
  9. Klijn J. G., Hoff A. M., Planting A. S., Verweij J., Kok T., Lamberts S. W., Portengen H., Foekens J. A. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer. 1990 Oct;62(4):627–630. doi: 10.1038/bjc.1990.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Krenning E. P., Kwekkeboom D. J., Bakker W. H., Breeman W. A., Kooij P. P., Oei H. Y., van Hagen M., Postema P. T., de Jong M., Reubi J. C. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716–731. doi: 10.1007/BF00181765. [DOI] [PubMed] [Google Scholar]
  11. Kuhn J. M., Legrand A., Ruiz J. M., Obach R., De Ronzan J., Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol. 1994 Sep;38(3):213–219. doi: 10.1111/j.1365-2125.1994.tb04344.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Qin Y., Schally A. V., Willems G. Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int J Cancer. 1992 Nov 11;52(5):791–796. doi: 10.1002/ijc.2910520520. [DOI] [PubMed] [Google Scholar]
  13. Reubi J. C., Horisberger U., Essed C. E., Jeekel J., Klijn J. G., Lamberts S. W. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology. 1988 Sep;95(3):760–763. doi: 10.1016/s0016-5085(88)80025-8. [DOI] [PubMed] [Google Scholar]
  14. Reubi J. C., Horisberger U., Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer. 1994 Mar 1;56(5):681–688. doi: 10.1002/ijc.2910560513. [DOI] [PubMed] [Google Scholar]
  15. Taylor J. E., Theveniau M. A., Bashirzadeh R., Reisine T., Eden P. A. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides. 1994;15(7):1229–1236. doi: 10.1016/0196-9781(94)90146-5. [DOI] [PubMed] [Google Scholar]
  16. Viollet C., Prévost G., Maubert E., Faivre-Bauman A., Gardette R., Kordon C., Loudes C., Slama A., Epelbaum J. Molecular pharmacology of somatostatin receptors. Fundam Clin Pharmacol. 1995;9(2):107–113. doi: 10.1111/j.1472-8206.1995.tb00269.x. [DOI] [PubMed] [Google Scholar]
  17. Virgolini I., Yang Q., Li S., Angelberger P., Neuhold N., Niederle B., Scheithauer W., Valent P. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994 Feb 1;54(3):690–700. [PubMed] [Google Scholar]
  18. Warshaw A. L., Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992 Feb 13;326(7):455–465. doi: 10.1056/NEJM199202133260706. [DOI] [PubMed] [Google Scholar]
  19. Weckbecker G., Liu R., Tolcsvai L., Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992 Sep 15;52(18):4973–4978. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES